KR870003781A - 지효성 조성물 - Google Patents

지효성 조성물 Download PDF

Info

Publication number
KR870003781A
KR870003781A KR1019860008977A KR860008977A KR870003781A KR 870003781 A KR870003781 A KR 870003781A KR 1019860008977 A KR1019860008977 A KR 1019860008977A KR 860008977 A KR860008977 A KR 860008977A KR 870003781 A KR870003781 A KR 870003781A
Authority
KR
South Korea
Prior art keywords
weight
formulation
cellulose ether
present
ether
Prior art date
Application number
KR1019860008977A
Other languages
English (en)
Other versions
KR890004685B1 (ko
Inventor
에이. 알더맨 다니엘
Original Assignee
리차드 지. 워터맨
더 다우 케미칼 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리차드 지. 워터맨, 더 다우 케미칼 캄파니 filed Critical 리차드 지. 워터맨
Publication of KR870003781A publication Critical patent/KR870003781A/ko
Application granted granted Critical
Publication of KR890004685B1 publication Critical patent/KR890004685B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

지효성 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. (1) 하나이상의 활성성분, (2) 7 내지 12중량%의 하이드록시프로폭실치환기 및 28 내지 30중량%의 메톡실치환기를 함유하며, 수평균분자량이 15,000 이상인, 미립자 크기의 거의 수용성인 하이드록시프로필 메틸셀룰로스에테르에테르, (3) 임의의 하나 이상의 담체 또는 부형제로 이루어진 고상의 약제학적 제제.
  2. 제1항에 있어서, 정제형태의 제제.
  3. 제1항에 있어서, 95중량% 이상의 셀룰로스에테르입자가 -100 메쉬스크린을 통과할 수 있는 제제.
  4. 제3항에 있어서, 95중량% 이상의 셀룰로스 에테르 입자가 -140 메쉬 스크린을 통과할 수 있는 제제.
  5. 제1항 또는 제4항에 있어서, 셀룰로스 에테르가 800cps 이상의 2% 용액 점도를 나타내는 제제.
  6. 제1항에 있어서, 부형제가 윤활제인 제제.
  7. 제1항 또는 제2항에 있어서, 활성성분이 약 95중량% 이하로 존재하고, 셀룰로스에테르가 5 내지 90중량%로 존재하며, 담체 또는 부형제가 약 3중량% 이하로 존재하는 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860008977A 1985-10-28 1986-10-27 지효성 조성물 KR890004685B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/791,675 US4734285A (en) 1985-10-28 1985-10-28 Sustained release compositions
US791,675 1985-10-28

Publications (2)

Publication Number Publication Date
KR870003781A true KR870003781A (ko) 1987-05-04
KR890004685B1 KR890004685B1 (ko) 1989-11-25

Family

ID=25154448

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860008977A KR890004685B1 (ko) 1985-10-28 1986-10-27 지효성 조성물

Country Status (6)

Country Link
US (1) US4734285A (ko)
JP (1) JPH0751516B2 (ko)
KR (1) KR890004685B1 (ko)
AU (1) AU599925B2 (ko)
CA (1) CA1285483C (ko)
NZ (1) NZ218046A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150031299A (ko) * 2012-07-17 2015-03-23 다우 글로벌 테크놀로지스 엘엘씨 고도로 치환된 하이드록시알킬 메틸셀룰로즈를 포함하는 고체 분산물

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU47044B (sh) * 1987-03-11 1994-12-28 LEK TOVARNA FARMACEVTSKIH IN KEMIČNIH IZDELKOV n.sol.o. Postupak za dobijanje tableta sa produženim delovanjem na bazi hidroksipropil-metilceluloze velike molekularne mase
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4973470A (en) * 1989-06-26 1990-11-27 Warner-Lambert Company Sustained release pharmaceutical compositions
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5281584A (en) * 1992-02-28 1994-01-25 The Dow Chemical Company Effect of particle-size distribution of cellulose ethers on palatability of compositions
JP2686215B2 (ja) * 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5938990A (en) * 1994-07-01 1999-08-17 Roche Vitamins Inc. Encapsulation of oleophilic substances and compositions produced thereby
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
IN186245B (ko) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
ATE424810T1 (de) 1998-12-11 2009-03-15 Nostrum Pharmaceuticals Inc Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
EP1652522A4 (en) * 2003-08-04 2008-11-26 Kyorin Seiyaku Kk PROLONGED RELEASE TABLET FOR ORAL ADMINISTRATION
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
CN101304764B (zh) 2005-11-11 2012-12-05 旭化成化学株式会社 控释固体制剂
NZ570704A (en) * 2006-02-10 2011-09-30 Mannatech Inc All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
EP2146696B1 (en) * 2007-04-13 2020-01-22 Dow Global Technologies LLC Granular material for dosage forms
JP2010529142A (ja) 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US9693959B2 (en) 2010-07-28 2017-07-04 Dow Global Technologies Llc Method of controlling the release of an active ingredient from a dosage form
CN106188581B (zh) 2011-04-06 2019-08-16 陶氏环球技术有限责任公司 生产具有高堆积密度和良好流动性的纤维素衍生物的方法
MX337827B (es) * 2011-04-06 2016-03-22 Dow Global Technologies Llc Novedosos derivados polisacaridos y formas de administracion.
BR112014020719B1 (pt) * 2012-04-11 2020-03-03 Dow Global Technologies Llc Forma de dosagem de liberação constante, método para preparar uma forma de dosagem de liberação constante e uso de um éter de celulose
EP2968578B1 (en) 2013-03-12 2019-06-26 Hercules LLC Coprocessed silica coated polymer composition
KR102519854B1 (ko) * 2016-10-07 2023-04-10 신에쓰 가가꾸 고교 가부시끼가이샤 히드록시알킬 알킬 셀룰로오스 및 그의 제조 방법, 및 고형 제제
KR102519850B1 (ko) * 2016-10-07 2023-04-10 신에쓰 가가꾸 고교 가부시끼가이샤 히드록시알킬 알킬 셀룰로오스 및 그의 제조 방법, 및 고형 제제
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
US20220062305A1 (en) 2018-12-18 2022-03-03 DDP Specialty Electronic Materials US, Inc. Sustained release composition comprising an ethylcellulose
WO2020131801A1 (en) 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxypropyl methylcellulose acetate succinate
WO2020131784A1 (en) 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a methylcellulose
EP3897728A1 (en) 2018-12-18 2021-10-27 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxyalkyl methylcellulose
WO2020131785A1 (en) 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxypropyl methylcellulose acetate succinate
JP2022515067A (ja) 2018-12-18 2022-02-17 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー メチルセルロースを含む徐放性組成物
WO2020131800A1 (en) 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising an ethylcellulose
US20230321061A1 (en) * 2022-04-11 2023-10-12 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065413A (en) * 1945-09-29 1962-11-20 Bell Telephone Labor Inc Magnetic gradiometer system
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE2050701C3 (de) * 1969-10-17 1979-12-20 Shinetsu Chemical Co., Tokio Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3951821A (en) * 1972-07-14 1976-04-20 The Dow Chemical Company Disintegrating agent for tablets
JPS5438167B2 (ko) * 1974-04-27 1979-11-19
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4269859A (en) * 1979-04-19 1981-05-26 Brown Company Cellulose floc granules and process
JPS5657719A (en) * 1979-10-16 1981-05-20 Asahi Chem Ind Co Ltd Preparation of pharmaceutical
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4528125A (en) * 1983-03-03 1985-07-09 The Dow Chemical Company Sustained release compositions
JPS59193815A (ja) * 1983-04-15 1984-11-02 Daicel Chem Ind Ltd 錠剤の製法
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
US4477657A (en) * 1983-07-08 1984-10-16 The Dow Chemical Company Process for preparing hydroxyalkylcellulose ethers
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150031299A (ko) * 2012-07-17 2015-03-23 다우 글로벌 테크놀로지스 엘엘씨 고도로 치환된 하이드록시알킬 메틸셀룰로즈를 포함하는 고체 분산물

Also Published As

Publication number Publication date
JPS62149632A (ja) 1987-07-03
US4734285A (en) 1988-03-29
JPH0751516B2 (ja) 1995-06-05
CA1285483C (en) 1991-07-02
AU599925B2 (en) 1990-08-02
AU6394786A (en) 1987-04-30
KR890004685B1 (ko) 1989-11-25
NZ218046A (en) 1990-04-26

Similar Documents

Publication Publication Date Title
KR870003781A (ko) 지효성 조성물
FI864665A (fi) Lääkeaineille tarkoitettuja kantajakoostumuksia, jotka sisältävät hydroksipropyyliselluloosaeettereitä
KR890004686A (ko) 서방성 에토돌락
KR950703952A (ko) 부분 경화된 식물성 오일이 코팅된 시메티딘 과립(Cimetidine Granules Coated with a Partially Hydrogenated Vegetable Oil)
KR880000089A (ko) 서방형 약제 조성물
UA41887C2 (uk) Фармацевтична композиція, що зазнає ерозію
KR960703570A (ko) 부형제와 함께 프로게스테론 및 폴리에틸렌글리콜을 함유하는 경구투여용 신규약제(a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together wtth an excipient)
DE69031950T2 (de) Kleine partikeln enthaltende arzneistoffzusammensetzung
DK0525389T3 (da) Fremgangsmåde til fremstilling af mekanisk stabile, let henfaldende tabletter af formlegemer, som indeholder aktivt stof
AR069281A2 (es) Composicion farmaceutica de liberacion sostenida y uso de la misma para preparar medicamentos
KR870000069A (ko) 안정한 고체 제형의 제조 방법
BRPI9712618B1 (pt) Tada e droga contida no comprimido.
CA2150464A1 (en) A pharmaceutical formulation for intraduodenal administration
IE40025B1 (en) Hexahydro-dibenzo (b,d) pyran-9-ones as psychotropic or sedative drugs
DK233080A (da) Overtraeksmiddel til foedevarer og medicinalvarer fremgangsmaade til fremstilling deraf samt produkter forsynet med et saadant overtraek
KR880701551A (ko) 제약적 처방
DK624287A (da) Komprimeret tablet eller kapsel
CA2157323A1 (en) Gepirone dosage form
FI894673A (fi) Produkter innehaollande psyllium.
ME00530B (me) Farmaceutske kompozicije tizoksanida i nitazoksanida
CA2502582A1 (en) Pharmaceutical formulation of olanzapine
KR880004801A (ko) 서방성 약학적 조성물
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제
KR870010082A (ko) 구아르(guar) 분말
KR900015732A (ko) 경구용 제제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050912

Year of fee payment: 17

EXPY Expiration of term